Showing posts with label James Carroll. Show all posts
Showing posts with label James Carroll. Show all posts

Friday, August 16, 2019

NEW HOPE FOR CANCER PATIENTS


PUBLISHED ON NEWSMAX

https://www.newsmax.com/scotfaulkner/photobiomodulation-pbm-cancer-oral-mucositis/2019/08/15/id/928715/

A new era of cancer treatment just dawned, giving hope to America's 15.5 million cancer survivors, and the estimated 1.8 million who will be diagnosed with cancer this year.

On June 22, 2019, the Multinational Association of Supportive Care in Cancer (MASCC) recommended the use of Photobiomodulation (PBM) as the standard of care for preventing and treating the side effects of radiotherapy and chemotherapy. 

The tragic challenge of fighting cancer is that the treatments severely damage the patient’s body.  Chemotherapy, radiotherapy and stem cell transplants can cause inflammation and the formation of ulcers inside the mouth.  The painful sores make it painful to eat.  In severe cases, known as oral mucositis (OM), patients can no longer swallow food.

OM occurs in close to 40 percent of patients receiving chemotherapy and nearly 80 percent of patients receiving radiation therapy, according to the Centers for Disease Control. 

OM can disrupt cancer therapy.  The pain is excruciating.  A feeding tube is usually required, sometimes cancer therapy is suspended so the patient can recover.  Under these circumstances, the cancer treatment may be less effective, and patients can become depressed and demoralized by these multiple shocks to their system.  Quality of life is significantly diminished.

Photobiomodulation (PBM) is a light therapy treatment that helps fortify the oral tissues, reducing pain and inflammation and promoting repair. It works by improving energy production in cells by stimulating their mitochondria, which can absorb this light and use it to increase energy (ATP) production and reduce the free radicals (ROS) that cause inflammation and cell death. Under these circumstances, tissues heal and become more resilient. Energized mitochondria repair cells and restore them to being fully functioning. The patient’s side effects disappear. PBM use, as part of the preparation for chemotherapy, prevents the side effects from occurring in the first place.

This medical breakthrough led to MASCC recommending PBM as the standard of care for all cancer patients who develop OM or are at risk of developing OM.

PBM was discovered in 1967.  It remained mostly in research laboratories in until the 21st Century. Now researchers at major medical schools and pioneering hospitals, are exploring the clinical applications of PBM for the brain, heart, eye, spinal cord, neuropathic pain and hard to heal wounds.  They recognize that the 32 trillion cells in the human body are the battleground for how the body remains healthy in the face of disease, injury, and aging.

Oncologists at the University of Pittsburgh Medical Center (UPMC), and other cancer centers, started to treat patients with PBM and are documenting the excellent results.  UPMC has treated over 850 cancer patients with PBM, significantly diminishing the side effects of cancer therapies.  Preventing OM eliminates treatment interruption, leading to a substantial increase in “progress free” cancer survivability.  Lessening side effects meant shorter hospital stays, less readmissions, and reducing overall cost of care.

PBM's success and safety recently led St. Jude Children’s Research Hospital to start using it on their pediatric cancer patients. 

In 2018, Britain’s National Institute for Care Excellence (NICE) adopted PBM as their standard of care for preventing OM.  Health plans in other countries have followed, building momentum for MASCC’s recommendation at their international meeting. 

“This a major milestone for the field and we are confident it will set a clear path for several exciting clinical applications for Photobiomodulation therapy from concussions and wound healing to exciting new work with regenerative medicine and stem cells,” said Dr. Praveen Arany, President of the World Association for Photobiomodulation Therapy.

Arany is one of the leaders of the movement to establish PBM as a mainstream treatment.  Four thousand published research papers, featured in major medical journals like the Lancet, and over seven hundred Randomized Controlled Trials (RCTs) are building the case for broader applications of PBM.  Clinical evidence is proving PBM Therapy is effective for musculoskeletal, neuropathic, and traumatic pain.  

The National Library of Medicine (NML) has recognized the legitimacy of PBM’s role in fortifying cells by accepting Photobiomodulation (PBM) as an official Medical Subject Heading.  The NLM catalogue contains more than 6,000 articles on the medicinal effects of light on cells and helping the body’s ability to defend itself and regenerate.

“PBM Therapy is more than just a form of pain relief, it actually helps patients heal”, explained James Carroll, CEO of THOR Photomedicine, a PBM device manufacturer.

The MASCC recommendation is an historic milestone and a major turning point in making Photobiomodulation the future of medicine.  Healthcare professionals and their patients are looking forward to updating other standards of care as PBM moves into the medical mainstream.

Thursday, January 17, 2019

ENDING OPIOIDS BY PHOTOBIOMODULATION

GUEST CONTRIBUTOR – James D. Carroll
Congressional Briefing on Ending Opioid Use by
treating pain using Photobiomodulation
Rayburn House Office Building
October 11, 2018

Mr. Chairman, members of Congress ladies and gentlemen. I am James Carroll, CEO and founder of THOR Photomedicine.

I am sure are all too aware there is an opioid crisis. A hundred million adults in the United States are affected by chronic pain and $600 billion a year is spent on in health care, direct health care costs and lost productivity because of pain.

49,000  people from opioids in 2017, 19,000 of which were from prescribed opioids for pain relief.

So we believe that Photobiomodulation therapy can help reduce the prescribing of opioid medication for pain relief and we wish to draw attention to the Congress and health care policymakers, NIH and CMS, about this potentially valuable tool.

I will start at the beginning, what is photobiomodulation therapy?

Some of you may have seen a TV show in the past called Star Trek.

On Star Trek when somebody was injured they would be taken to sickbay, and the doctor would get out a laser beam and aim it at the injury, and the patients would heal instantly, well that is photobiomodulation.

It is not as fast as on TV, we don't heal people instantly, but you get the idea, we shine a special kind of light on people, and they get better more quickly.

So what is this Photobiomodulation?

Photobiomodulation (PBM) Therapy previously known as Low-Level Laser Therapy (LLLT) is the application of monochromatic light which means light of one color, and if we have light at the right color (or to use the technical phrase the right wavelength) and if the light is of the right intensity, and if we aim it in the right place, for the right amount of time, then we can increase the speed of tissue repair, we can reduce inflammation and edema, and we can induce an analgesic effect.

Most of the published clinical evidence is on musculoskeletal pain (sprains and strains and creaky joints), but there is also evidence for its effect on neuropathic pain, non-healing wounds and oral mucositis a severe side effect of chemotherapy and radiotherapy for which opioids are often prescribed.

Treatments look like this, usually directly to the skin or an injury and it can be intraoral, it can be extraoral, we can do some remote treatments as well.



Photobiomodulation (PBM) is not a heat therapy, the effects on the body are more like photosynthesis in plants because humans and animals will photosynthesize, and you know this already but you not have thought about it before, but you know when we go out in the sun we change color, that is a form of photosynthesis, and we use light to help synthesize vitamin D, and you may know that in hospitals they treat premature babies with blue light to prevent neonatal jaundice, and you may know that dermatologists  use ultraviolet light for treating psoriasis and vitiligo, so we should not be surprised if light has some other effects on the body.

Normally you and patients and many doctors will associate lasers in medicine with cutting and cauterizing tissue. The good news is that not all lasers are dangerous,  some of them are more dangerous than others and that's because there are different classes of lasers. 


Class one lasers are inherently safe, they are used in supermarkets for reading barcodes and nobody gets hurt. The medical lasers you are probably thinking of are Class 4 lasers, they're the ones that have a thermal effect.

PBM Therapy uses Class 3B lasers, they have no harmful effects on skin or clothing but they are potentially hazardous to the eyes. So everybody should be wearing laser safety glasses when PBM lasers are being used, but PBM Therapy also utilizes light-emitting diodes (LEDs), they have some similar qualities to lasers but they also have they have no harmful effects and are usually safe for the eyes.

For the sake of this presentation, we are going to assume that lasers and LEDs do the same thing because mostly they do, we do not have time today to explain when it is best to use lasers or when it might be best to use LEDs.

There are 500 randomized placebo control clinical trials published on PBM and yet most people in medicine have never even heard of it.

There are over 4,000 laboratory studies looking at the mechanism of action and dose-response, and about thirty peer-reviewed research papers are published every month in this field.

Some of the popular medical applications of PBM Therapy include: hard to heal wounds (such as diabetic foot ulcers, venous ulcers and pressure sores), musculoskeletal pain such as tendinopathies, neck pain (as reviewed here in The Lancet).


Reduced use of opioids for Post-operative pain. Postherpetic Neuralgia one of the worst pains that you can get. It’s chronic persistence hypersensitivity and in some patients and its really severe,  people can’t wear shirts and they can’t lie down, they can’t bear to be touched, it drives some people to suicide. At the end of the study 95% of patients discontinued all medication. At 6-month follow-up 80% maintained their reduction in pain.



Oral mucositis is a painful, debilitating side effect of high dose chemotherapy and radiotherapy often requiring opioids for pain control. Thirty-three clinical trials (RCTs) have shown PBM Therapy to be effective in reducing the incidence and severity of oral mucositis.


The Multinational Association for Supportive Care in Cancer (MASCC) recommend the use of PBM Therapy for treating oral mucositis, and in the United Kingdom the National Institute of Health and Care Excellence  (NICE) recommend cancer patients receive this treatment in the UK National Health Service (NHS).


It has been shown in one long term follow-up Oral Mucositis study on 108 patients followed up to 8 years that the active PBM threated group had better long term (cancer) progression-free survival than those in the placebo group.

How can one medicine treat so many different diseases?

You know you shouldn’t believe anything that appears to do everything. PBM does not do everything, it treats one thing and it treats it very well, it is something scientists call it Reactive Oxygen Species (ROS), doctors call it Oxidative Stress, and most patients would call them Free Radicals

Light has a profound effect on the production of ROS, but where do they come from? They come from mitochondria. So what are mitochondria? Well, mitochondria are often called the powerhouses of the cell. 




The short story is; when we're sick, injured, stressed or just old, our cells tend to be low on ATP,  high in oxidative stress, when we put PBM Therapy into patients it tips the balance in favor of more ATP and less oxidative stress, and under these circumstances patients get better and more quickly.



PBM Therapy is safe and effective for a wide range of medical conditions where drugs and surgery have failed. It is time for this proven procedure to be considered as a first line medical treatment.

This is not just another form of pain relief, it actually helps people heal.

For more information visit: www.CONGRESSPBM.com


James Carroll has been working on Photobiomodulation for over 30 years (since1987). He is a recognized authority on Photobiomodulation dose, dose rate effects and the measurement and reporting of parameters. He has written or co-authored 18 published academic papers and three books on Laser Photobiomodulation. His most recent appointments include: Biomedical Optics Society conference chair, Fellow of The Royal Society of Medicine, and Editorial Board of Photomedicine and Laser Surgery. He also served on the World Association for Laser Therapy and the North American Association for Laser Therapy. James recently presented Photobiomodulation to the United Nations Global Health Impact Forum.

Friday, October 26, 2018

ENDING OPIOID USE



Published on Newsmax.

Those suffering from America’s opioid crisis recently received two major messages of hope.

On October 24, President Donald Trump signed the Opioid Crisis Response Act (OCRA) into law. Dozens of bills designed to address the diverse aspects of the opioid crisis were consolidated into one strategic and integrated approach. OCRA received overwhelming bi-partisan support in both Chambers.

HR6, which is now Public Law 115-271, broke new ground in being the first legislation to mandate aggressive development and adoption of alternative pain treatments that include innovative medical technologies for pain management”.

On October 11, Congress held its first ever briefing on ending opioid use through “innovative medical technologies for pain management”.

Photobiomodulation (PBM) was the featured technology.

James Carroll (CEO, THOR Photomedicine), Professor Praveen Arany (New York University at Buffalo), Annette Quinn RN (Radiation Oncology, University of Pittsburgh (UPMC) Cancer Center) introduced the science and promise of PBM Therapy to a capacity crowd of senior policy officials from House and Senate offices, the Executive Branch, and leading think tanks. Nineteen science and medical organizations sponsored this historic gathering.

PBM Therapy delivers a beam of light, which when applied to the body at the right wavelength (red to near infra-red), intensity and time, reverses the disease process of a growing number of medical conditions. It works by delivering light to the hundreds of mitochondria that exist in every one our body’s 37 trillion cells. This provides an energy boost that helps the cells repair and operate at peak performance.

There are already 500 clinical trials and 4,000 laboratory studies that show PBM Therapy’s effectiveness, without any documented side-effects. "PBM Therapy is commonly used in Australia, Brazil, Canada, New Zealand, and most European nations. The national health programs in many of these countries cover PBM treatments.”

The United States has been slow to embrace PBM Therapy. American Veterinarians and athletes have used it for years to treat pain. The urgency of the opioid crisis, and the new mandate for pain treatment alternatives, may finally bring this proven approach to those who need it.

The study mandated by the newly signed Opioid Crisis Response Act (OCRA) will be led by the Secretary of Health and Human Services (HHS). This is important, as Medicare and Medicaid can dramatically reduce health costs when patients use PBM Therapy. Quicker recovery time, no side effects, shorter hospital stays, and reduced return visits have cut costs by nearly fifty percent in the United Kingdom. PBM use would substantially reduce costs to both patients and private health insurance companies.

The next steps for PBM Therapy adoption are mandated in the OCRA law, including research grants to fund further basic science experiments, therapeutic dose, and large multi-center clinical trials. OCRA also funds “regional centers of excellence” to develop curriculum and train the next generation of healthcare professionals in non-opioid pain treatments.

Harvard University’s Medical School is discovering that PBM reverses Alzheimer’s, Parkinson’s, treats depression and Post-traumatic stress disorder (PTSD). Boston University is working with the Veterans Administration on depression, traumatic brain injury (TBI), and PTSD. University of Pittsburgh’s Medical Center and New York University’s Medical College are proving that PBM Therapy reverses and even prevents the side effects of cancer radiotherapy, especially oral mucositis.

Shepherd University will be the first nursing school in America to formally include PBM Therapy in their curriculum. Shepherd is leading the way on revolutionizing medical protocols for the betterment of patients and their loved ones. Hopefully, other schools will join the PBM Therapy movement.

The Food and Drug Administration (FDA) has spent over a year determining how to expand its PBM Therapy approval. This includes establishing a dedicated PBM Product Code, and officially recognizing PBM treatments are curative, not just temporary relief. It is time for the FDA to move forward.

After years of tragedy and death, the battle to rid America of opioid use disorder is starting to turn the tide. This promise of hope will become a reality only when PBM Therapy receives the funding, acceptance, and adoption it deserves.

Saturday, May 12, 2018

SEEING THE LIGHT


Also published on Newsmax.  #PBMTherapyHeals

Imagine being successfully treated, painlessly and safely, for a wide range of diseases and conditions. Imagine having a cure for chronic pain.

This revolution in health and wellness is already available and will be celebrated on May 16 as the United NationsAnnual International Day of Light.

On May 16, 1960, American physicist and engineer, Theodore Maiman, operated the first successful laser, achieving coherent and controllable light waves. This revolutionized manufacturing, communications, and health.

In 1967, Endre Mester in Semmelweis University Budapest, Hungary conducted studies to determine if lasers caused cancer. He shaved the hair from the bodies of mice, divided them into two groups and gave a laser treatment with a low powered ruby laser to one group. They did not get cancer. Instead the hair on the treated group grew back more quickly than the untreated group. The concept of "laser biostimulation" was discovered.

Today, “biostimulation” is known as Photobiomodulation (PBM). It is the process where a specific range of the light spectrum at the right intensity, when directed to the body for the right period of time, can restore the function of stressed cells to normal healthy operation. It is non-invasive, non-toxic, and has no reported side effects.

There are over 32 trillion cells in the human body. Each cell has hundreds of microscopic factories called mitochondria which combine oxygen with nutrients from the blood stream to make the cellular energy called ATP. This energy is used to help the cell live and to conduct its various roles in our body: keeping the heart beating, the brain thinking, the body moving, and the all the other functions that keep us alive and healthy.

Mester’s discovery was an epiphany. If specific light band waves can help cells to regrow hair, can they wake-up cells to do other things? Now over five-hundred human clinical trials and 4,000 laboratory studies have shown the answer to be an overwhelming YES!

PBM is now a common veterinary treatment for improving the lives of animals suffering from hip dysplasia and kidney failure. Throughout the world, forward thinking Doctors and Dentists are using PBM to successfully treat Oral Mucositis (side effect from chemotherapy), Dry Macular Degeneration, Multiple Sclerosis, Parkinsons Disease, Lyme Disease, and diabetic wounds. It also reduces pain and inflammation in various orthopedic conditions such as tendonitis, neck pain, low back pain, and carpal tunnel syndrome.

Chronic pain costs Americans over $635 billion a year in additional healthcare costs and lost productivity. PBM is used for recovery and endurance by champion athletes. At the 2016 Rio Olympics, many Nike sponsored athletes used a whole body PBM product called NovoTHOR to help them train, recover, and win more medals. This led NFL, MLB, NHL and NBA teams to add “light beds” to their training regime.

A growing number of doctors and public health officials are exploring PBM therapy as an alternative pain treatment to Opioids. This may help solve the addiction crisis facing America.

If PBM is so effective, why is not everywhere?

Outside of the U.S. it is. Australia, Canada, England, the European Union, and NATO all recognize PBM, promote its use, and accept insurance coverage. The Food and Drug Administration (FDA) is slowly moving towards regulatory clearances for PBM light equipment to officially treat diseases and conditions. Currently, the FDA labels PBM devices in the basic category of infrared or heat lamps.

Until the FDA moves forward, U.S. insurance companies, except for a few BCBS affiliates, refuse to reimburse for PBM treatments. They remain a solid wall of resistance.

Medicare and Medicaid refuse to reimburse for PBM treatments. Federal Officials have labeled PBM “mumbo jumbo” and declared its successes placebo effect”.

The International Day of Light is an opportunity to alert everyone who could benefit from PBM therapy of its existence and promise. It is a time to ask public officials about ways to bring PBM into the mainstream of American healthcare. It is a time to ask your Doctor, Dentist, Veterinarian, and local gym/wellness center if they offer PBM therapy and if not, why not.

May 16 is an annual reminder that bringing light therapy into healthcare is long overdue.

It is up to all of us, for ourselves, our families, and our communities, to make the promise of light a reality.

[Scot Faulkner advises global organizations and universities on healthcare reform and innovation. He served as the Chief Administrative Officer of the U.S. House of Representatives. He also served on the White House Staff, and as an Executive Branch Appointee.]